Office Action Predictor
Last updated: April 16, 2026
Application No. 17/676,931

Cobalt-Porphyrin Complexes for the Inactivation of the Biological Activity of Opioids

Final Rejection §112
Filed
Feb 22, 2022
Examiner
SZNAIDMAN, MARCOS L
Art Unit
1628
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Government Of The United States Of America, As Represented By The Secretary Of The Navy
OA Round
2 (Final)
37%
Grant Probability
At Risk
3-4
OA Rounds
3y 6m
To Grant
39%
With Interview

Examiner Intelligence

Grants only 37% of cases
37%
Career Allow Rate
461 granted / 1253 resolved
-23.2% vs TC avg
Minimal +2% lift
Without
With
+1.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
56 currently pending
Career history
1309
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
38.8%
-1.2% vs TC avg
§102
17.2%
-22.8% vs TC avg
§112
26.8%
-13.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1253 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This office action is in response to applicant’s reply filed on December 15, 2025. Status of Claims Amendment of claims 1 and 3 is acknowledged. Claims 1-9 are currently pending and are the subject of this office action. Claim 5-9 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on January 21, 2025. Claims 1-4 are presently under examination. Priority The present application is a CON of 16/837,342 filed on 04/01/2020, which claims benefit to provisional application No. 62/829,140 filed on 04/04/2019. Rejections and/or Objections and Response to Arguments Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated (Maintained Rejections and/or Objections) or newly applied (New Rejections and/or Objections, Necessitated by Amendment or New Rejections and/or Objections not Necessitated by Amendment). They constitute the complete set presently being applied to the instant application. Responses to Applicant’s arguments have been addressed immediately after the corresponding rejections, or in the section: Withdrawn Rejections and/or Objections, if the rejection was withdrawn. Claim Rejections - 35 USC § 112 (New Rejection Necessitated by Amendment). The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-4 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. This is an enablement rejection. To be enabling, the specification of the patent application must teach those skilled in the art how to make and use the full scope of the claimed invention without undue experimentation. In re Wright, 999 F.2d 1557, 1561 (Fd. Cir. 1993). Explaining what is meant by "undue experimentation," the Federal Circuit has stated that: The test is not merely quantitative, since a considerable amount of experimentation is permissible, if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which experimentation should proceed to enable the determination of how to practice a desired embodiment of the claimed invention. PPG v. Guardian, 75 F.3d 1558, 1564 (Fed. Cir. 1996). As pointed out by the court in In re Angstadt, 537 F.2d 498 at 504 (CCPA 1976), the key word is "undue", not "experimentation". The factors that may be considered in determining whether a disclosure would require undue experimentation are set forth In re Wands, 8 USPQ2d 1400 (CAFC 1988) at 1404 wherein, citing Ex parte Forman, 230 USPQ 546 (Bd. Apls. 1986) at 547 the court recited eight factors: 1- the quantity of experimentation necessary, 2- the amount of direction or guidance provided, 3- the presence or absence of working examples, 4- the nature of the invention, 5- the state of the prior art, 6- the relative skill of those in the art, 7- the predictability of the art, and 8- the breadth of the claims These factors are always applied against the background understanding that scope of enablement varies inversely with the degree of unpredictability involved. In re Fisher, 57 CCPA 1099, 1108, 427 F.2d 833, 839, 166 USPQ 18, 24 (1970). Keeping that in mind, the Wands factors are relevant to the instant fact situation for the following reasons: 1. The nature of the invention Claims 1-4 recite a material comprising the porphyrin (meso-tri-(4-sulfonatophenyl)-mono-(4-carboxyphenyl)-porphine (C1S3TPP)) coordinated with cobalt, wherein the porphyrin has the following structure: PNG media_image1.png 424 446 media_image1.png Greyscale 2. The relative skill of those in the art The relative skill of those in the art is high, generally that of an Organic Chemist. 3. The state and predictability of the art A search of the literature revealed that the above structure is novel. However, it is well known in Organic chemistry that: certain functional groups or atoms within molecules can carry a positive or negative charge, and that the total charge of the molecule is zero. For example, sodium chloride and sodium acetate are examples of these molecules and are represented respectively as: Na+ Cl- and Na+ CH3COO-. Further, there is no knowledge in the prior art of the existence of the Na2 molecule. In fact, a search on STN of the above molecule shows the correct representation, wherein all the charges are assigned: PNG media_image2.png 120 594 media_image2.png Greyscale PNG media_image3.png 346 338 media_image3.png Greyscale 4. The amount of direction or guidance provided and the presence or absence of working examples The specification discloses the synthesis of the claimed compound as follows: PNG media_image4.png 406 566 media_image4.png Greyscale As discussed above, the molecule claimed by Applicant: PNG media_image1.png 424 446 media_image1.png Greyscale does not exist, since the positive and negative charges of the different groups within the molecule are missing. Further, there is no knowledge in the prior art of the existence of the Na2 molecule. As such, making the above molecule is scientifically unattainable. The correct structure, as shown by STN search is: PNG media_image3.png 346 338 media_image3.png Greyscale 6. Conclusion Accordingly, the inventions of claims 1-4 do not comply with the enablement requirement of 35 U.S.C 112, first paragraph, since to practice the claimed invention a person of ordinary skill in the art would have to engage in undue experimentation with no assurance of success. Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARCOS L SZNAIDMAN whose telephone number is (571)270-3498. The examiner can normally be reached Flexing M-F 7 AM-7 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L. Clark can be reached on 571 272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MARCOS L SZNAIDMAN/ Primary Examiner, Art Unit 1628 December 17, 2025.
Read full office action

Prosecution Timeline

Feb 22, 2022
Application Filed
Jan 21, 2025
Response after Non-Final Action
Aug 10, 2025
Non-Final Rejection — §112
Dec 15, 2025
Response Filed
Jan 11, 2026
Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594261
Use of Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases
2y 5m to grant Granted Apr 07, 2026
Patent 12589089
PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS
2y 5m to grant Granted Mar 31, 2026
Patent 12576057
ANTIBACTERIAL AND BIOFILM FORMATION-INHIBITING COMPOSITION CONTAINING MYRISTOLEIC ACID AS ACTIVE INGREDIENT
2y 5m to grant Granted Mar 17, 2026
Patent 12570659
BICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS
2y 5m to grant Granted Mar 10, 2026
Patent 12558328
SOLID-FORMING TOPICAL FORMULATIONS FOR PAIN CONTROL
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
37%
Grant Probability
39%
With Interview (+1.8%)
3y 6m
Median Time to Grant
Moderate
PTA Risk
Based on 1253 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in for Full Analysis

Enter your email to receive a magic link. No password needed.

Free tier: 3 strategy analyses per month